A bioinformatical approach used to find indications for drug
repositioning to produce new treatment paradigms for
schizophrenia by comparing the binding profiles of currently
available clinical compounds to targets or sets of targets derived
from genome-wide association studies (GWAS) or other genetic
studies. Thank you for your question!